NO20064982L - 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav - Google Patents
1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse deravInfo
- Publication number
- NO20064982L NO20064982L NO20064982A NO20064982A NO20064982L NO 20064982 L NO20064982 L NO 20064982L NO 20064982 A NO20064982 A NO 20064982A NO 20064982 A NO20064982 A NO 20064982A NO 20064982 L NO20064982 L NO 20064982L
- Authority
- NO
- Norway
- Prior art keywords
- oxadiazole
- ones
- delta modulators
- ppar delta
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55841904P | 2004-04-01 | 2004-04-01 | |
PCT/US2005/010854 WO2005097762A2 (fr) | 2004-04-01 | 2005-03-30 | 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064982L true NO20064982L (no) | 2006-10-31 |
Family
ID=34972933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064982A NO20064982L (no) | 2004-04-01 | 2006-10-31 | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav |
Country Status (17)
Country | Link |
---|---|
US (1) | US7576109B2 (fr) |
EP (1) | EP1735303B1 (fr) |
JP (1) | JP4813460B2 (fr) |
KR (1) | KR20060135854A (fr) |
CN (1) | CN100516065C (fr) |
AT (1) | ATE507226T1 (fr) |
AU (1) | AU2005230837A1 (fr) |
BR (1) | BRPI0509468A (fr) |
CA (1) | CA2561738A1 (fr) |
DE (1) | DE602005027677D1 (fr) |
IL (1) | IL178167A0 (fr) |
MA (1) | MA28562B1 (fr) |
NO (1) | NO20064982L (fr) |
NZ (1) | NZ550857A (fr) |
RU (1) | RU2375358C2 (fr) |
WO (1) | WO2005097762A2 (fr) |
ZA (1) | ZA200607851B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ549823A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US7968723B2 (en) | 2004-05-05 | 2011-06-28 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
EP2298742B1 (fr) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | acides phénoxyacétiques en tant qu'activateurs PPAR delta |
AU2006299086A1 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridyl-1, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma Inc | ácidos fenóxi acéticos como ativadores de ppar delta |
CA2645719A1 (fr) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composes, leur preparation et utilisation |
US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
US20120020931A1 (en) * | 2010-06-02 | 2012-01-26 | Rutgers, The State University Of New Jersey | Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells |
WO2015035171A1 (fr) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895953A (en) * | 1987-09-30 | 1990-01-23 | American Home Products Corporation | 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
US4826990A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
DE60032898T2 (de) * | 1999-06-18 | 2007-10-25 | Merck & Co., Inc. | Arylthiazolidindion- und aryloxazolidinderivate |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
AU7115300A (en) * | 1999-09-08 | 2001-04-10 | Glaxo Group Limited | Oxazole ppar antagonists |
JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
NZ549823A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
-
2005
- 2005-03-30 AU AU2005230837A patent/AU2005230837A1/en not_active Abandoned
- 2005-03-30 CN CN200580010054.5A patent/CN100516065C/zh not_active Expired - Fee Related
- 2005-03-30 JP JP2007506540A patent/JP4813460B2/ja not_active Expired - Fee Related
- 2005-03-30 WO PCT/US2005/010854 patent/WO2005097762A2/fr active Application Filing
- 2005-03-30 NZ NZ550857A patent/NZ550857A/en unknown
- 2005-03-30 CA CA002561738A patent/CA2561738A1/fr not_active Abandoned
- 2005-03-30 BR BRPI0509468-2A patent/BRPI0509468A/pt not_active IP Right Cessation
- 2005-03-30 AT AT05766888T patent/ATE507226T1/de not_active IP Right Cessation
- 2005-03-30 DE DE602005027677T patent/DE602005027677D1/de active Active
- 2005-03-30 RU RU2006138485/04A patent/RU2375358C2/ru not_active IP Right Cessation
- 2005-03-30 KR KR1020067020431A patent/KR20060135854A/ko not_active Application Discontinuation
- 2005-03-30 EP EP05766888A patent/EP1735303B1/fr active Active
-
2006
- 2006-09-18 IL IL178167A patent/IL178167A0/en unknown
- 2006-09-19 ZA ZA200607851A patent/ZA200607851B/en unknown
- 2006-09-26 US US11/535,227 patent/US7576109B2/en not_active Expired - Fee Related
- 2006-10-31 NO NO20064982A patent/NO20064982L/no not_active Application Discontinuation
- 2006-10-31 MA MA29428A patent/MA28562B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN1938305A (zh) | 2007-03-28 |
EP1735303A2 (fr) | 2006-12-27 |
NZ550857A (en) | 2009-12-24 |
MA28562B1 (fr) | 2007-04-03 |
BRPI0509468A (pt) | 2007-09-11 |
JP2007531763A (ja) | 2007-11-08 |
US7576109B2 (en) | 2009-08-18 |
ZA200607851B (en) | 2008-06-25 |
CA2561738A1 (fr) | 2005-10-20 |
IL178167A0 (en) | 2006-12-31 |
EP1735303B1 (fr) | 2011-04-27 |
KR20060135854A (ko) | 2006-12-29 |
DE602005027677D1 (de) | 2011-06-09 |
CN100516065C (zh) | 2009-07-22 |
AU2005230837A1 (en) | 2005-10-20 |
ATE507226T1 (de) | 2011-05-15 |
WO2005097762A3 (fr) | 2005-12-15 |
WO2005097762A2 (fr) | 2005-10-20 |
US20070060626A1 (en) | 2007-03-15 |
JP4813460B2 (ja) | 2011-11-09 |
RU2006138485A (ru) | 2008-05-10 |
RU2375358C2 (ru) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
DK1780197T3 (da) | 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer | |
EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
WO2008030412A3 (fr) | Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
NO20082496L (no) | Pyrazinderivater | |
EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
EP1817312A4 (fr) | Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer | |
DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
DE602005014629D1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
EP2073635A4 (fr) | Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |